Tag: bladder cancer therapeutics market trends
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval of Trodelvy for bladder cancer therapeutics market
According to the study of the American Society of Clinical Oncology (ASCO), urothelial carcinoma accounts for around 90%, squamous cell carcinoma accounts for 4%, and adenocarcinoma accounts for 2% of all bladder cancer.
0
0
0
3 Aug, 11:11 AM
